CD38 and plasma cell myeloma: Furthermore, scholars developed liposome‐based multispecific T‐cell engagers (nanoMuTEs), decorating with anti‐CD3 mAbs and multiple mAbs, including anti‐BCMA, anti‐CS1, and anti‐CD38 mAbs, against myeloma cells simultaneously.